Optimisation of treatments, therefore, firstly to select the patients who are intrinsically sensitive to EGFR inhibitors and, secondly, to delay the outgrowth of drug-resistant tumours during EGFR targeted therapy, could provide better treatment options. This evidence concerns the gene EGFR and neoplasm.